Novo Nordisk has secured UK regulatory approval to market Wegovy as an oral tablet, offering patients an alternative to the weekly injection format. The daily pill version addresses a barrier that has limited adoption among some patients who prefer oral medication or have needle anxiety.
The injectable form of semaglutide, marketed as Wegovy, has dominated the weight-loss drug market since its rapid rise in 2023. The GLP-1 receptor agonist drives significant appetite suppression and has generated billions in revenue for Novo Nordisk while creating supply shortages that have periodically disrupted the market. The oral formulation represents a strategic move to expand the addressable patient population beyond those willing or able to self-administer weekly shots.
This pill rollout follows earlier approvals in other markets. The tablet format operates at different dosing than the injection, requiring daily administration rather than weekly doses. Clinical trials have shown comparable efficacy between oral and injectable semaglutide for weight management, though patient adherence patterns may differ given the commitment required for daily dosing versus once-weekly administration.
The UK launch comes as Novo Nordisk faces intensifying competition in the weight-loss drug space. Rival pharmaceutical companies are advancing their own GLP-1 candidates, and the market continues expanding beyond diabetes management into obesity treatment. Demand remains robust, with millions of patients globally seeking approved weight-loss pharmacotherapy.
Healthcare systems and private payers will need to evaluate whether the oral formulation justifies separate reimbursement pathways or pricing considerations. For patients, the pill option removes injection-related obstacles while introducing the new challenge of daily medication compliance. Novo Nordisk positions this move as expanding choice rather than replacing the injectable option, which will remain available for patients who prefer weekly dosing.